Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
MOTS-c vs. Cagrilintide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceVery limited comparison
At least one comparison profile is still being completed. Use the underlying compound records for the evidence currently available.
✓ Shared
Shared Similarities
- Neither record represents a broadly FDA-approved treatment.
⇄ Different
Biggest Difference
MOTS-c is distinguished by mOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA. Human studies mostly measure the body's own MOTS-c; administered treatment evidence remains preclinical while a Phase 2a trial is enrolling; Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
MOTS-c is distinguished in the current record by mOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA. Human studies mostly measure the body's own MOTS-c; administered treatment evidence remains preclinical while a Phase 2a trial is enrolling. Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceCagrilintide
MOTS-c: Profile in progress. Cagrilintide: Developing human evidence.
Regulatory historyComparable
MOTS-c: Investigational. Cagrilintide: Investigational — Phase 3.
Mechanistic breadthCagrilintide
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
MOTS-c
- Insulin sensitivity and prediabetes
- Metabolic homeostasis
- Exercise response
- Aging and healthspan
Cagrilintide
- Weight management
- Appetite and energy intake
- Obesity with type 2 diabetes
- Visceral and ectopic fat
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
MOTS-cInvestigational
Investigational
CagrilintideInvestigational
Investigational. No FDA-approved standalone cagrilintide product, consumer dose, reconstitution method, or official storage procedure.
Evidence depthEvidence, not a winner
MOTS-cProfile in progress
Endogenous MOTS-c changes with exercise and is associated with some human metabolic phenotypes, but no completed controlled efficacy results for administered native MOTS-c were available.
CagrilintidePhase 2 + Phase 3 pending
One published 706-participant Phase 2 monotherapy trial, a 105-participant thorough-QT study, sponsor-reported Phase 3 component-arm data, and two active dedicated Phase 3 RENEW trials without posted results.
Weight outcomesEvidence, not a winner
MOTS-cRecord incomplete
No dedicated weight-outcome summary has been editorially approved.
CagrilintidePeer-reviewed Phase 2
Phase 2 reported mean reductions of 6.0% to 10.8% across studied cagrilintide arms versus 3.0% placebo at 26 weeks. A sponsor-reported Phase 3 component arm later reported 11.8% versus 2.3% at 68 weeks under an efficacy estimand.
Type 2 diabetesEvidence, not a winner
MOTS-cRecord incomplete
No dedicated diabetes-outcome summary has been editorially approved.
CagrilintidePhase 3 registered
RENEW 2 is studying standalone cagrilintide in adults with overweight or obesity and type 2 diabetes; no results were posted by the cutoff.
Obstructive sleep apnoeaEvidence, not a winner
MOTS-cRecord incomplete
No dedicated obstructive-sleep-apnoea outcome summary has been editorially approved.
CagrilintideNo dedicated evidence
No dedicated completed controlled human obstructive-sleep-apnoea outcome study was located.
Cardiovascular outcomesEvidence, not a winner
MOTS-cRecord incomplete
No dedicated cardiovascular-outcome summary has been editorially approved.
CagrilintideQT study only
A 105-participant thorough-QT study found no clinically relevant QTc prolongation at the tested exposure. That narrow result is not a cardiovascular outcomes trial.
Administration and handlingEvidence, not a winner
MOTS-cOpen profile
Open the compound profile for approved-label information or clearly identified trial-administration records.
CagrilintideTrial descriptions only
Published and registered studies describe once-weekly subcutaneous administration under protocol-specific escalation. These are trial descriptions, not approved dosing instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Very limited comparison
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Whether administered native MOTS-c improves meaningful human outcomes and whether repeated exposure is safe.
- Whether the dedicated RENEW Phase 3 trials confirm long-term standalone efficacy and safety in people with and without type 2 diabetes.
Community Intelligence
Emerging patterns, clearly separated from evidence
MOTS-c
No community experiences yetBe the first account holder to contribute.
Cagrilintide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.